NEWTOWN, PA — Traws Pharma, Inc. (Nasdaq: TRAW) said it has completed enrollment in a 90-patient Phase 2 study testing its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results